|
A Gynmed csapata elkötelezetten törekszik arra, hogy a fogamzásgátlás és az abortusz jogi szabályozása, valamint a nők orvosi ellátása tökéletesedjen.
Ennek érdekében tapasztalatainkat és az új tényeket publikáljuk. Az alábbiakban megtalálja a csapatunk tagjainak részvételével született német és angol nyelvű szakmai írások listáját. Contraception:The Gynmed Team is highly engaged in further improving the laws and regulations on contraception and abortion as well as the care and medical treatment of women. To this goal we publish new insights and findings. Following please find a list of articles from medical journals written or co-authored by members of the team. The publications are in English and German. Securing reproductive rights Fiala C, Weeks A, Safar P. Lancet. 2004 Mar 20;363(9413):989-90 Abortion:Evaluation of Early Medical Abortion (EMA) Pilot Sites Roger Ingham and Ellie Lee et al. University of Southampton and Department of Health, London www.dh.gov.uk Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol Aronsson A, Fiala C, Stephansson O, Granath F, Watzer B, Schweer H, Gemzell-Danielsson K. Hum Reprod. 2007 Jul;22(7):1912-8 www.ncbi.nlm.nih.gov Frequently asked clinical questions about medical abortion, WHO, 2006 www.who.int Review of medical abortion using mifepristone in combination with a prostaglandin analogue Fiala C, Gemzel-Danielsson K. Contraception 2006 Jul;74(1):66-86 www.ncbi.nlm.nih.gov Pharmacokinetics of a novel oral slow-release form of misoprostol Fiala C, Aronsson A, Granath F, Stephansson O, Seyberth HW, Watzer B, Gemzell-Danielsson K. Hum Reproduction 2005 Dec;20(12):3414-8 www.ncbi.nlm.nih.gov Effects of slow release misoprostol on uterine contractility in early pregnancy C. Fiala, A. Aronsson, O. Stephansson and K. Gemzell-Danielsson Human Reproduction 2005 Sep;20(9):2648-52. www.ncbi.nlm.nih.gov The effect of non-steroidal anti-inflammatory drugs (NSAIDs) on medical abortion with mifepristone and misoprostol at 13 to 22 weeks gestation C. Fiala, ML. Swahn, O. Stephansson, and K. Gemzell-Danielsson Human Reproduction 2005 Nov;20(11):3072-7 www.ncbi.nlm.nih.gov Abortion in Europe: Are the Laws and Practices patient centered? Christian Fiala Entre Nous magazine, UNFPA/ WHO No. 59 – 2005, page 23-5 download pdf Acceptability of home-use of misoprostol in medical abortion Fiala C, Winikoff B, Helstrom L, Hellborg M, Gemzell-Danielsson K. Contraception. 2004 Nov;70(5):387-92. www.ncbi.nlm.nih.gov Rh-prophylaxis in early abortion Fiala C, Fux M, Gemzell Danielsson K. Acta Obstet Gynecol Scand. 2003 Oct;82(10):892-903. Review www.ncbi.nlm.nih.gov Verifying the effectiveness of medical abortion; ultrasound versus hCG testing Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Eur J Obstet Gynecol Reprod Biol. 2003 Aug 15;109(2):190-5. www.ncbi.nlm.nih.gov Medical abortion - where we are in Europe Christian Fiala, Entre Nous magazine, UNFPA/ WHO No 47-48; Autumn 2000: 16-17 Other topics: Misoprostol and the debate over off-label drug use Weeks AD, Fiala C, Safar P British Journal of Obstetrics and Gynaecology. 2005 Mar;112(3):269-72. www.misoprostol.org
|